Sangamo: Pipeline Expansion Via Partnership And Internal ST-503 Development

Terry Chrisomalis
Investing Group Leader

Summary

  • Sangamo Therapeutics, Inc. received IND clearance to initiate a phase 1/2 study for ST-503 targeting idiopathic small fiber neuropathy, a type of chronic neuropathic pain condition.
  • SGMO entered a deal with Astellas, allowing the use of its STAC-BBB capsid for the development of up to 5 neurological disorders; a $20 million upfront payment & $1.3 billion milestone payments.
  • The global Neuropathic Pain market size is projected to grow to $14.05 billion by 2032.
  • Pfizer is in discussions with multiple regulatory authorities seeking to obtain marketing approval for Giroctocogene for the treatment of patients with moderate-to-severe Hemophilia A.
  • Looking for a portfolio of ideas like this one? Members of Biotech Analysis Central get exclusive access to our subscriber-only portfolios. Learn More »

H2 Hydrogen Molecule Fuel Cell Element

Just_Super/iStock via Getty Images

The last time I spoke about Sangamo Therapeutics, Inc. (NASDAQ:SGMO) it was regarding a Seeking Alpha article entitled “Sangamo: Fabry Disease Gene Therapy Moves Forward With Positive FDA Regulatory Development.

This article is published by Terry Chrisomalis, who runs the >Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33.50% discount price of $399 per year.

This article was written by

Terry Chrisomalis
13.5K Followers

Terry Chrisomalis is a private investor in the Biotech sector with years of experience utilizing his Applied Science background to generate long term value from Healthcare.

He is the author of the investing group Biotech Analysis Central which contains a library of 600+ Biotech investing articles, a model portfolio of 10+ small and mid-cap stocks with deep analysis for each, live chat, and a range of analysis and news reports to help Healthcare investors make informed decisions.

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

About SGMO Stock

SymbolLast Price% Chg
Market Cap
PE
Yield
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on SGMO

Related Stocks

SymbolLast Price% Chg
SGMO
--
Compare

Trending Analysis

Trending News